在初级纤维动力障碍中,氧化合成酶活性受损 - - 数据驱动的假设
Lisa Eggenkemper1,2, Anne Schlegtendal1, Christoph Maier1
1University Children's Hospital, Ruhr-University Bochum, 44791 Bochum, Germany.
初级状腺失动症 (PCD) 显示肺部氧化 (NO) 合成受损,与囊性纤维化 (CF) 不同. 这项研究研究了PCD,CF和健康对照患者的L-氨酸/NO途径.
科学领域:
- 肺部医学 肺部医学
- 生物化学 生物化学
- 医学研究 医学研究
背景情况:
- 低鼻氧化 (nNO) 是初级动力障碍症 (PCD) 的特征.
- nNO有助于区分PCD与其他肺部疾病,如囊性纤维化 (CF).
- 在PCD中NO失调背后的机制仍然不清楚.
研究的目的:
- 在患有PCD,CF和健康对照 (HC) 的患者中研究L-氨酸/NO (Arg/NO) 途径.
- 了解PCD中NO失调的病理机制.
主要方法:
- 一项前性,受控研究,涉及24名PCD患者,25名CF患者和14名HC患者.
- 在唾液,血和尿液中测量NO前体 (L-氨酸,同氨酸),氨酸酶代谢物 (氨酸),NO抑制剂 (不对称的二甲基氨酸) 和NO代谢物 (酸盐,酸盐) 的含量.
- 使用验证的分析方法来量化代谢物.
主要成果:
- 与HC和CF相比,PCD中的液L-氨酸和ADMA度在PCD中显著更高.
- 唾液中酸盐和酸盐水平在PCD患者中低于HC和CF患者.
- 血和尿液中的代谢物度在所有研究组中都是可比的.
结论:
- PCD与肺部中氧化合成受损有关,与CF不同.
- 在PCD中观察到的NO失调可能与机械化学解有关.
- 需要进一步的研究来阐明PCD中NO缺乏的确切机制.
更多相关视频
09:03Nasal Brushing Sampling and Processing Using Digital High Speed Ciliary Videomicroscopy – Adaptation for the COVID-19 Pandemic
Published on: November 7, 2020
11:13Collection, Expansion, and Differentiation of Primary Human Nasal Epithelial Cell Models for Quantification of Cilia Beat Frequency
Published on: November 10, 2021
相关概念视频
Nitric Oxide Signaling Pathway
Mechanism of Ciliary Motion
The cilia are made up of microtubules in a 9+2 arrangement, with nine microtubule doublet ring bundles, surrounding a pair of central singlet microtubule bundles. The doublet microtubule bundles are...
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation
COPD: Pathogenesis and Clinical Features
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
Antihypertensive Drugs: Vasodilators
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
